On Nov. 13, 2017, the Department of Transportation (DOT) published a final rule that, among other items, expands DOT’s current drug testing panel to include certain semi-synthetic opioids (i.e., hydrocodone, oxycodone, hydromorphone, oxymorphone). Testing for methylenedioxyethylamphetamine (MDEA) has been removed while methylenedioxyamphetamine (MDA) has been added as an initial test analyte.
The final rule also clarifies existing drug testing program provisions and definitions, makes technical amendments and removes the requirement for employers and Consortium/Third Party Administrators to submit blind specimens. The final rule becomes effective Jan. 1, 2018.
“The opioid crisis is a threat to public safety when it involves safety-sensitive employees involved in the operation of any kind of vehicle or transport,” said DOT Secretary Elaine L. Chao. “The ability to test for a broader range of opioids will advance transportation safety significantly and provide another deterrence to opioid abuse, which will better protect the public and ultimately save lives.”
Click here to read more from DOT.
Click here to read the final rule as published in the Federal Register.
Related News
- Senate Passes Tax Bill Without Including Railroaders
- Canada Day 2025: General President Coleman’s message to members
- SMART-TD Honors the Retirement of Brother Greg Hynes: A Visionary, a Fighter, and a Legend
- SMART-TD Calls on U.S. Senate to Support the Cantwell Amendment and Protect Rail Workers
- Yardmaster Protection Act Introduced
- PHOTO GALLERY: 2025 Denver Regional Training Seminar
- Fighting for Stronger Heat Protections for Rail Workers
- Regional Training Seminar Sets (Mile-High) Record in Denver
- Registration Open for Anaheim Regional Training Seminar
- Local 9 wins work-creating law for members in Colorado